Asian Journal of Research in Cardiovascular Diseases

In silico Investigation of the Bioactive Component of Zingiber Officinale (GINGER) as a Potential Inhibitor of Angotensin-Converting Enzyme (ACE) in Hypertension

Abdullahi Muhammed Hassan *

Department of Biochemistry, Nasarawa State University, PMB 1022, Keffi, Nigeria.

Abdullahi Halimatu Sadiya

Department of Biochemistry, Nasarawa State University, PMB 1022, Keffi, Nigeria.

Adeu Magdalene Nguher

Department of Biochemistry, Nasarawa State University, PMB 1022, Keffi, Nigeria.

*Author to whom correspondence should be addressed.

---

Abstract

Hypertension is a long-term medical condition in which the blood pressure in the arteries is persistently elevated. Hypertension is a primary risk factor for a number of chronic health conditions and the major cause of premature death worldwide. Several new target and diseases pathway are emerging one of such is the Angiotensin Converting Enzymes (ACE), which is a central component of the renin–angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. It converts the hormone angiotensin I to the active vasoconstrictor angiotensin II. Therefore, ACE indirectly increases blood pressure by causing blood vessels to constrict. This study explored the anti-hypertensive potential of the bioactive compounds found in Zingiber Officinale. In the study, 122 natural compounds obtained from literature were used for molecular docking against the ACE receptor target using the Python Prescription (PyRx) 0.8 software. An arbitrary score ≤ -7.3 kcal/mol was chosen as a cut-off value. 21 compounds were obtained after cutoffs which were further screened using Lipinkis, Ghose, and Verber rule regarding Rotatable bond (RB), TPSA, Saturation, Molar Refractivity (MR), and PAIN alert, resulting in 15 compounds. Pharmacokinetic screening (ADMET and bioactivity) was carried out on the compounds, and it was discovered that 5 compounds (Zenimbone, Delta Cadinene, Beta-Eudesmol, and Alpha Eudesmol and Ledol) are good drug candidates and have an effect on the protein (ACE) and have high potency to reduce hypertension.

Keywords: Hypertension, Angiotensin Converting Enzymes (ACE), Zingiber officinale, Renin–Angiotensin System (RAS), In-silico

---

---

---

References

WHO. Hypertension. World health organization; 2023. Available:https://www.who.int/news-room/fact-sheets/detail/hypertension

Naish J, Court DS. Medical sciences (2 ed.). 2014:562.

ISBN 9780702052491.

Lackland DT, Weber MA. "Global burden of cardiovascular disease and stroke: hypertension at the core". The Canadian Journal of Cardiology. 2015;31(5):569–571.

Lau DH, Nattel S, Kalman JM, Sanders P. modifiable risk factors and atrial fibrillation. Circulation (Review). 2017;136(6).583-596. DOI:10.1161/CIRCULATIONAHA.116.023163

PMID 28784826.

Kaplan's essentials of cardiac anesthesia. Mechanisms of action: ACE inhibitors act by inhibiting one of several proteases responsible for cleaving the decapeptide Ang I to form the octapeptide Ang II. Because ACE is also the enzyme that degrades bradykinin, ACE inhibitors increase circulating and tissue levels of bradykinin. Elsevier; 2018. DOI:10.1016/c2012-0-06151-0

ISBN 978-0-323-49798-5.

Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. The Journal of Biological Chemistry. 2005;280(45):37644–37650. DOI: 10.1074/jbc.M508460200

PMC 2409196. PMID 16154999.

Coates D. The angiotensin converting enzyme (ACE)". The International Journal of Biochemistry & Cell Biology. Renin–Angiotensin Systems: State of the Art. 2003;35(6):769–773. DOI: 10.1016/S1357-2725(02)00309-6

PMID 12676162.

Zhang R, Xu X, Chen T, Li L, Rao P. An assay for angiotensin-converting enzyme using capillary zone electrophoresis. Analytical Biochemistry. 2000;280(2):286–290. DOI: 10.1006/abio.2000.4535

PMID 10790312.

Byrd JB, Ram C, Venkata S, Lerma EV. Pharmacologic treatment of hypertension. Nephrology Secrets. Elsevier. ACE inhibitors inhibit the conversion of angiotensin I to angiotensin II, thereby producing vasodilation and lowering BP. Because the hydrolysis of bradykinin is also inhibited by these drugs, cough (7% to 12%) can occur. 2019;477–482. DOI: 10.1016/b978-0-323-47871-7.00078-2.

ISBN 978-0-323-47871-7.

Yeh GY, Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol. 2006;98(5):673–680.

Sanghal A, Pant KK, Natu SM, Nischal A, Khattri S, Nath R. An experimental study to evaluate the preventive effect of Zingiber officinale (ginger) on hypertension and hyperlipidaemia and its comparison with Allium sativum (garlic) in rats. Journal Medicinal Plants Res. 2012;6(25):4231–4238.

Mao QQ, Xu XY, Cao SY, Gan RY, Corke H, Beta T, Li HB. Foods. 2019;8:185–206. Available:https://doi.org/10.3390/foods8060185

Daina A, Michielin O, Zoete V. Swiss ADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports. 2017; 7:42717.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews. 2001;46(1-3):3-26

Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of Combinatorial Chemistry. 1999;1:55-68

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry. 2002;45(12):2615-2623.

Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. The Journal of Medicinal Chemistry. 2000;43:3867–3877.

Muegge I, Heald SL, Brittelli D. Simple selection criteria for drug-like chemical matter. The Journal of Medicinal Chemistry. 2001;44:1841–1846.

Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry. 2015;58(9):4066-72. DOI: 10.1021/acs.jmedchem.5b00104.

Molinspiration cheminformatics. Calculation of molecular properties and bioactivity score; 2020. Available:http://www.molinspiration.com/cgi-bin/properties Accessed 8th December 2020

Hopkins AL. Pharmacological space in the practice of medicinal chemistry. (4th ed.). USA: Elsevier. 2015;395-408.

Khanna V, Ranganathan S. Physiochemical property space distance among human metabolites, drugs and toxins. BMC Bioinformatics. 2009;10(15):S10.

Hansch C, Bjorkroth JP, Leo A. Hydrophobicity and the central nervous system agents: on the principle of minimal hydrophobicity in drug design. Journal of Pharmaceutical Sciences. 1987;76(9):663-687.

Chen X, Li H, Tian L. Analysis of the physio-chemical properties of acaricides based on Lipinski’s Rule of 5. Journal of Computational Biology. 2020;27:1397-1406.

Putra PP, Abdullah SS, Rahmatunisa R. Structure, activity, and drug-likeness of pure compounds of Sumatran lichen (Stereocaulon halei) for the targetd ACE2 protein in COVID-19 disease. Pharmacina. 2020;10:135.

Medjahed S, Belaidi S, Djekheba S. Computational study of molecular electrostatic potential, drug-likeness screening and structure-activity/property relationships of thiazolidine-2,4-dione derivatives. Journal of Bionanoscience. 2016;10:118-126.

Oprea TI. Property distribution of drug-related chemical databases. Journal of Computer-Aided Molecular Design. 2000;14(3):251–264. Available:https://doi.org/10.1023/a:1008130001697

Guan L, Yang H, Cai Y, Sun L, Di P, Li W, Liu G, Tang Y. ADMET-Score- a comprehensive scoring function for evaluation of chemical drug-likeness. Comprehensive Medicinal Chemistry. 2019;10(1):148-157.

Cui Q, Lu S, Ni B, Zeng X, Tan Y, Chen YD, Zhao H. Improved prediction of aqueous solubility of novel compounds by going deeper with deep learning. Frontiers in oncology. 2020;10:121.

Hou T, Wang J, Li Y. ADME evaluation in drug discovery. 8. The prediction of human intestinal absorption by a support vector machine. Journal of chemical Information and Modelling. 2007;47(6): 2408-2415.

Supe S, Takudage P. Methods for evaluating penetration of drug into the skin: A review. Skin Research and Technology. 2021;27(3):299-308.

Pardridge WM. Drug transport across the blood–brain barrier. Journal of Cerebral Blood Flow & Metabolism. 2012; 32(11):1959-1972.

Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & therapeutics. 2013; 138(1):103-141.

Horde GW, Gupta V. Drug clearance. Government medical college Amritsar. Study guide from statpearls publishing, Treasure Island (FL); 2020.

PMID: 32491690

Stampfer HG, Gabb GM, Dimmitt SB. Why maximum tolerated dose?. British Journal of Clinical Pharmacology. 2019;85(10): 2213-2217.

Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. Journal of hepatology. 1997; 26:26-36.

Kuddus M. Introduction to food enzymes. Enzymes in Food Biotechnology. 2019: 1-18.